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USDA Regulation of Animal Biotechnology
In this presentation I will share with you a U.S. Department of Agriculture (USDA) perspective on some of the regulatory issues associated with animal 
biotechnology. You are all aware of the Federal Coordinated Framework for bio-
technology oversight that has moved products of biotechnology from the labora-
tory to the marketplace. Under this policy, federal agencies use their existing 
statutory authority to regulate the products of biotechnology.
The product reviews focus on the nature of the product and the risk, rather 
than the process used in its development. Federal agencies are required to ensure 
protection for public health and the environment from any potential harmful ef-
fects of these products. Favorable evaluations of the job the agencies are doing 
were published by the U.S. General Accounting Office and by the Office of Tech-
nology Assessment in 1988.
The “Report on National Biotechnology Policy,” released by the Council on 
Competitiveness in the Office of the Vice President in 1991, reaffirmed the 
Administration’s commitment to maintaining the U.S. lead in biotechnology re-
search and product development over the long-term. The report provided an up-
date on the Coordinated Framework and restated several principles for guiding 
federal regulatory policy:
—Federal oversight should focus on the characteristics and risks of the prod-
uct, not the process, used in its development;
—Regulatory review should be designed to minimize burden while assuring 
protection of public health and welfare;
—Regulatory programs should be responsive to rapid advances in bio-
technology.
The Council on Competitiveness’ report also recommended publication of a 
document to help federal agencies make decisions, within the scope of au-
thority afforded by statute, on how to regulate planned introductions of bio-
technology products. The statement was published in February, 1992. It will 
ensure that federal oversight is used where it will do the most good—that is, 
where the risks are real.
We are using these principles to refine the management of our biotechnology 
programs at USDA. I would like to mention some of our management initiatives 
and then discuss the regulation of animal biotechnology.
USDA has both research and regulatory responsibilities for agricultural 
biotechnology and they are administered separately. The Assistant Secretary 
for Marketing and Inspection Services oversees the Department’s biotechnol-
ogy regulatory activities through a delegation of authority from the Secretary 
of Agriculture.
The counterpart for research is the Assistant Secretary for Science and 
Education. Together they co-chair the Committee on Biotechnology in Agri-
culture (CBA) which was established in 1986 as USDA’s policy-making and 
coordinating body for biotechnology.
The members of the CBA are the administrators of all the USDA agen-
cies that administer biotechnology programs—the Animal and Plant Health 
Inspection Service (APHIS), the Food Safety and Inspection Service (FSIS), 
Agricultural Research Service, the Cooperative State Research Service, the 
Economic Research Service and the Forest Service.
The CBA met recently (Spring, 1992) to review a strategy that we believe 
will improve the effectiveness of our biotechnology programs. Several of 
these initiatives are the result of a study of USDA management of critical is-
sues, including biotechnology, that cut across the jurisdiction of individual 
agencies:
—We have solicited proposals for the biotechnology risk assessment re-
search program stipulated in the 1990 Farm Bill. The purpose of the program 
is to strengthen the scientific basis of USDA’s regulatory programs.
—We approved a public information plan on biotechnology for the De-
partment. This is a priority program. We have been providing information 
for a long time on an agency-by-agency basis and the time has come to 
launch a Department-wide effort. We began the program this spring by co-
sponsoring a joint U.S. and European Community (EC) meeting on biotech-
nology communication in Dublin, Ireland.
—USDA agencies are implementing the President’s Biotechnology Re-
search Initiative. This involves reporting and monitoring of the Department’s 
$162.6 million 1992 research budget for biotechnology and reassessing our 
research priorities.
—We are committed to fostering trade through scientific meetings that 
will lead to international consensus on biosafety issues. USDA scientists are 
involved in the negotiations sponsored by the major international organiza-
tions including the EC and the Organization for Economic Cooperation and 
Development (OECD).
REGULATING PRODUCTS OF ANIMAL BIOTECHNOLOGY
Now I will turn to the activities of the two USDA regulatory agencies directly 
concerned with regulating the products of animal biotechnology—APHIS 
and FSIS. Both agencies have authority, in the broadest sense, for protecting 
animal health.
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Animal and Plant Health Inspection Service (APHIS)
The Virus-Serum-Toxin Act of 1913, as amended, gives APHIS the authority 
to regulate all veterinary biological products imported into the U.S. or ex-
ported, or those biologics shipped or delivered for shipment interstate or 
intrastate.
Veterinary biological products are defined in the regulations [9 CFR 
101.2(w)] as all viruses, serums, toxins and analogous products of natural or 
synthetic origin intended for use in the diagnosis, treatment or prevention of 
diseases of animals.
The licensing requirements [9 CFR Part 102] include tests to insure pu-
rity, safety, potency and efficacy. Pre-licensure evaluation of all veterinary 
biological products—regardless of the techniques used in their develop-
ment—is performed at the National Veterinary Services Laboratory (NVSL) 
in Ames, Iowa. The NVSL is the only federal facility in the U.S. engaged in the 
evaluation of veterinary biologies and the diagnosis of domestic and foreign 
animal diseases.
It was nearly ten years ago that APHIS issued the first license for a veteri-
nary biological product developed through biotechnological techniques. 
Since then, 48 product licenses have been granted for three broad categories 
of these products. The categories are based on the biological characteristics 
of the product and the kinds of safety issues it presents. Category one in-
cludes inactivated recombinant DNA-derived vaccines, bacterins, bacterin- 
toxoids and virus or bacterial subunits.
Hybridoma-derived monoclonal antibodies as well as genetically engi-
neered antibodies are also included in this category. These nonviable, or 
killed, products pose no risk to the environment and present no new safety 
concerns. An example of a category one product is the Escherichia coli 
bacterin used to protect swine against Colibacillosis, a disease that has severe 
economic effects on swine producers.
The diagnostic test kits classified as category one products represent a 
significant breakthrough in animal disease diagnosis and treatment. Pseudo-
rabies diagnostic test kits which can differentiate between reactions caused 
by wild type viral infections and immunization with recombinant vaccines, 
are used in APHIS’ Pseudorabies Eradication Program.
Category two products contain live microorganisms that have been 
modified by the addition of marker genes or the deletion of genes that code 
for virulence. Special precautions are taken to ensure that the addition or de-
letion of genetic information does not confer virulence, pathogenicity or sur-
vival advantages to these organisms that are greater than those found in the 
parent or wild type forms. All the licensed category two products are for use 
against pseudorabies in swine and involve gene deletions or additions.
Category three includes products containing live expression vectors car-
rying recombinant DNA-derived sequences that code for immunizing antigens
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or other immune stimulants. The transmission characteristics of such prod-
ucts must be carefully assessed before field studies are undertaken.
While no licenses have been granted in category three, one product is 
currently being field tested after a thorough evaluation of safety data. The 
product is a live recombinant DNA-derived vaccine-vectored rabies vaccine 
intended for oral use in raccoons in the wild. The incidence of rabies has in-
creased dramatically in the Mid-Atlantic States and public health officials 
have been enthusiastic about the potential of immunizing animals in the wild 
with the recombinant vaccine contained in food bait. Field tests have been 
conducted on Parramore Island in Virginia and in Sullivan County, Pennsylvania.
Additional tests have begun in a three-county area in New Jersey. Since 
December, 1989, there have been 1700 cases of rabies in New Jersey and 90 
percent of the cases have been in raccoons. The disease is moving from North 
to South in the State and New Jersey public health authorities hope to estab-
lish a rabies-free zone by concentrating the bait drops in Cape May County. 
There will be extensive monitoring before and after another bait drop in 
Fall, 1992.
The states must approve field tests of all experimental biologies so we 
have worked closely with state officials to provide the public with informa-
tion on the rabies vaccine field trials. APHIS scientists attended state-spon-
sored public meetings to answer technical and scientific questions and an 
APHIS spokesperson was interviewed in the Spring, 1992, on Cable News 
Network (CNN) about the New Jersey tests. The vaccine trials were also fea-
tured in a new publication on biotechnology distributed in March, 1992, to 
junior high school students throughout Pennsylvania.
Future generations of vaccines will combine the genetic information to 
immunize against several diseases into one virus or bacteria. We have now 
received an application for a genetically engineered category three vaccine 
with antigens against two disease agents in the same microorganism. This 
will improve the consistency of production from lot to lot of product, by 
eliminating variation in antigen content when different components are 
mixed together.
For the category two licenses and the field trials of the category three ra-
bies vaccine, APHIS prepared a complete environmental assessment of the 
proposed action in compliance with the provisions of the National Environ-
mental Policy Act. The environmental assessments provide the public with a 
discussion of scientific data on safety and a thorough analysis of environ-
mental impacts.
When any project has implications for public health, expert panels con-
sisting of representatives from federal agencies, academic institutions and 
professional societies are convened to review data. Additional review can 
also be requested from the National Vaccine Program in the Department of 
Health and Human Services which was done for the rabies vaccine.
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Early generations of veterinary biological products developed through 
biotechnology have proved effective in disease prevention and diagnosis. 
Succeeding generations will be even more effective and we look increasingly 
to global markets for these products.
The growth of international ownership of the biologics production in-
dustry and the advent of the European Community (EC) have increased the 
immediacy of the drive for internationally recognized standards and consis-
tency in testing procedures. We have worked with a number of international 
groups to further this process. In one of these efforts, U.S. and EC represen-
tatives met in France in January, 1992, to work toward the standardization of 
production practices. The discussions continued during that summer.
There is pressure on the U.S. to increase the potential for EC-produced 
biologics to enter U.S. markets. Many of these products are prevented entry 
because of the presence of foot and mouth disease and bovine spongiform 
encephalopathy in several EC countries. We are working to resolve these and 
a number of other issues.
Food Safety and Inspection Service (FSIS)
Turning now to the role of the Food Safety and Inspection Service in regulat-
ing animal biotechnology, this will be brief because Dr. Cross has already 
done such an able job on this subject (see page 121). The summary statement 
from last year’s NABC workshop on transgenic animals is a good place to be-
gin and I quote:
In general, workshop participants concluded that public issues 
associated with transgenics were not urgent, primarily because 
applications of transgenic technologies as they affect agriculture 
and the food supply seem remote at the present time. (Murray 
et al., 1991, p. 43)
We think that if we do our work well enough, public issues associated with 
transgenics will not become urgent. This means that we must continue to 
maintain an open dialogue on potential issues before they develop. We talk to 
our critics, as well as to the regulated public, and we join with other federal 
agencies in sponsoring workshops and discussion groups.
These statutes from which FSIS gets its authority for regulating the ani-
mal products of classical breeding and new technologies are the Federal Meat 
Inspection Act and the Poultry Products Inspection Act.
These statutes require that FSIS inspect cattle, sheep, swine, goats, 
equine, poultry and food products prepared from them intended for use in 
human food to assure that they are wholesome, not adulterated and properly 
labeled, marked and packaged. The FSIS policy statement in the 1986Coordi-
nated Framework established the applicability of the experimental animal 
regulations for the use of genetic engineering techniques in food animals 
[9CFR309.17and381.75].
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This policy was reaffirmed in a Federal Register notice published in De-
cember, 1991. The notice pointed out that only a small proportion of the ani-
mals in gene transfer experiments contain the intended gene [56 FR 67054- 
67055]. Before animals that do not contain the experimental transgene may 
be presented for slaughter, data must be submitted to FSIS demonstrating 
that the transgene is not present and that the animals are therefore “not adul-
terated.” Written approval for slaughter of an animal determined to be 
nontransgenic is granted by the FSIS Deputy Administrator for Inspection 
Operations and the animals are subject to the same inspection procedures as 
conventionally bred animals. Animals have been approved for slaughter un-
der these provisions. We expect a number of applications to be considered in 
the near future. We know that the cost of maintaining these animals is pro-
hibitively high.
A document is being prepared which pertains to the food safety evalua-
tion of transgenic animals being considered for slaughter. In making an 
evaluation, FSIS may consult with other agencies, including the Food and 
Drug Administration (FDA), the Environmental Protection Agency (EPA) 
and APHIS. Interaction among federal agencies to consider these issues has 
been taking place for several years through the meetings of the Food Animal 
Biotechnology Information Exchange Group. Through these discussions we 
are working to anticipate both scientific and consumer issues, and to avoid 
delays due to agency concerns about jurisdiction.
We know that research using molecular methods will bring revolution-
ary advances in animal science. The realization of much of this promise is in 
the future for the development of animals bred for special qualities such as 
disease resistance. However, this research has already brought us quantum 
increases in our knowledge of gene function. There have been many notable 
breakthroughs. Transgenic animals have proven very useful as models for the 
development and treatment of a variety of human diseases. The use of large 
animals as bioreactors has resulted in the development of sheep that secrete 
such substances as Clotting Factor 9 in their milk, and transgenic pigs that 
carry quantities of human hemoglobin in their blood.
There are any number of applications of biotechnology to animal science 
and production agriculture that are scientifically successful including the 
production and use of bovine and porcine growth hormones. One applica-
tion, in particular, must be singled out because it relates directly to the FSIS 
responsibilities for food safety. The availability of DNA probes to test for the 
presence of bacterial pathogens in meat and meat products has cut the detec-
tion time by one-half. These molecular methods are also highly sensitive and 
cost-effective.
The use of existing statutes and procedures to evaluate the products of 
animal biotechnology has allowed us to anticipate the testing and marketing 
of new products. We have ensured our capability for dealing with the new 
techniques by hiring specialists and through training programs for our staff
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scientists. We urge researchers to meet with us to discuss any questions they 
may have about regulations for testing and product development.
CONCLUSION
In closing, I would like to emphasize the point Dr. Cross made about the im-
portance of consumer interests and perceptions (see page 125). USDA agen-
cies, including FSIS and APHIS, work closely with consumer-interest groups 
to inform the public about our oversight policies and programs for biotech-
nology products and to discuss any safety concerns associated with produc-
tion and marketing.
The potential of biotechnology for improving animal health and the 
quality of meat and meat products is immense. We believe that risk-based 
regulatory programs will help realize the benefits of the technology for both 
U.S. consumers and producers.
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